Apogee Therapeutics (APGE) Total Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has reported Total Liabilities for 5 consecutive years, with $37.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 7.2% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $37.9 million (down 7.2% YoY), while the FY2025 annual figure was $33.3 million, down 10.51% from the prior year.
• Total Liabilities improved to $37.9 million in Q1 2026 per APGE's latest filing, from $33.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $41.9 million in Q3 2024 and bottomed at $10.0 million in Q4 2022.
• Historically, Total Liabilities has averaged $29.6 million across 5 years, with a median of $33.3 million in 2025.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 143.82% — and 2025, when it dropped 10.51%.
• Apogee Therapeutics' Total Liabilities stood at $10.0 million in 2022, then jumped by 115.34% to $21.5 million in 2023, then jumped by 72.9% to $37.2 million in 2024, then dropped by 10.51% to $33.3 million in 2025, then climbed by 13.86% to $37.9 million in 2026.
• Business Quant data shows APGE's Total Liabilities at $37.9 million in Q1 2026, $33.3 million in Q4 2025, and $39.8 million in Q3 2025.